Subtype
Primary Central Nervous System Neoplasm
CI-CAN-00001432Explore in graph →
Non-malignant957 active trials5 approved drugs175 evidence items
- NCIt
- C102871
Loading cancer entity…
Subtype
CI-CAN-00001432Explore in graph →
Clinical trials
3,293 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05635734 | Azeliragon and Chemoradiotherapy in Newly Diagnosed Glioblastoma | completed | Phase 1 / Phase 2 | 33 | Cantex PharmaceuticalsINDUSTRY | 1 | Sep 24, 2026 | clinicaltrials |
| NCT03174197 | Atezolizumab in Combination With Temozolomide and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma | completed | Phase 1 / Phase 2 | 60 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT03277638 | Laser Interstitial Thermotherapy (LITT) Combined With Checkpoint Inhibitor for Recurrent GBM (RGBM) | completed | Phase 1 / Phase 2 | 32 | Case Comprehensive Cancer CenterOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT04688151 | Rituximab, Acalabrutinib, and Durvalumab (RAD) in Primary CNS Lymphoma. | completed | Phase 1 | 22 | National Health Research Institutes, TaiwanOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT03657576 | Trial of C134 in Patients With Recurrent GBM(C134-HSV-1) | completed | Phase 1 | 19 | University of Alabama at BirminghamOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT04201873 | Pembrolizumab and a Vaccine (ATL-DC) for the Treatment of Surgically Accessible Recurrent Glioblastoma | completed | Phase 1 | 46 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT05036577 | A Dose-escalating Pilot Study of Orelabrutinib for Newly-diagnosed PCNSL(ORMD2021) | completed | Phase 1 | 13 | Huashan HospitalOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT03389802 | Phase I Study of APX005M in Pediatric Central Nervous System Tumors | completed | Phase 1 | 32 | Pediatric Brain Tumor ConsortiumNETWORK | 1 | Aug 13, 2026 | clinicaltrials |
| NCT03030066 | Study of DS-1001b in Patients With Gene IDH1-Mutated Gliomas | completed | Phase 1 | 47 | Daiichi SankyoINDUSTRY | 1 | Jul 28, 2026 | clinicaltrials |
| NCT05698199 | Study to Evaluate the Safety, Tolerability, Immunogenicity and Preliminary Efficacy of ITI-1001 In Patients With Newly Diagnosed Glioblastoma (GBM) | completed | Phase 1 | 10 | Immunomic Therapeutics, Inc.INDUSTRY | 1 | Jul 1, 2026 | clinicaltrials |
| NCT02303678 | D2C7 for Adult Patients With Recurrent Malignant Glioma | completed | Phase 1 | 81 | Darell BignerOTHER | 1 | Jun 26, 2026 | clinicaltrials |
| NCT07198087 | A Study to Investigate the Pharmacokinetics of Tirabrutinib in Participants With Mild, Moderate, and Severe Hepatic Impairment Compared to Healthy Participants | completed | Phase 1 | 40 | Ono Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 26, 2026 | clinicaltrials |
| NCT07635173 | SM-1 Combined With Temozolomide in Subjects With Refractory or Recurrent High-Grade Gliomas | completed | Phase 1 | 35 | Shenzhen Zhenxing Medical Technology Co., LtdOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT04911621 | Adjuvant Dendritic Cell Immunotherapy for Pediatric Patients With High-grade Glioma or Diffuse Intrinsic Pontine Glioma(ADDICT-pedGLIO) | completed | Phase 1 / Phase 2 | 10 | University Hospital, AntwerpOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT03514069 | Ruxolitinib With Radiation and Temozolomide for Grade III Gliomas and Glioblastoma | completed | Phase 1 | 60 | Case Comprehensive Cancer CenterOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT06668987 | A Study of the Boron Neutron Capture Therapy (BNCT) Using B10 L-BPA in Recurrent Meningioma | completed | Phase 1 / Phase 2 | 10 | Heron Neutron Medical Corp.INDUSTRY | 1 | May 11, 2026 | clinicaltrials |
| NCT04968366 | Safety & Efficacy of DC Vaccine and TMZ for the Treatment of Newly-diagnosed Glioblastoma After Surgery | completed | Phase 1 | 11 | Beijing Tiantan HospitalOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT03154996 | Chronic Convection Enhanced Delivery of Topotecan | completed | Phase 1 | 5 | Columbia UniversityOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT03451799 | Ketogenic Diet in Combination With Standard-of-care Radiation and Temozolomide for Patients With Glioblastoma | completed | Phase 1 | 21 | Jethro HuOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT02866747 | A Study Evaluating the Association of Hypofractionated Stereotactic Radiation Therapy and Durvalumab for Patients With Recurrent Glioblastoma(STERIMGLI) | completed | Phase 1 / Phase 2 | 108 | Institut Claudius RegaudOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT07497373 | A Phase I Study to Evaluate the Safety and Tolerability of JL15003 Injection in Patients With Recurrent Glioblastoma(JL15003) | completed | Phase 1 | 17 | Jecho Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Apr 3, 2026 | clinicaltrials |
| NCT06650605 | Phase 1 Open-label Study of 123I-ATT001 in Subjects With Relapsed Glioblastoma(CITADEL-123) | completed | Phase 1 | 7 | Theragnostics LtdINDUSTRY | 1 | Mar 31, 2026 | clinicaltrials |
| NCT04019002 | Hyperpolarized Carbon-13 (13C) Pyruvate Imaging in Patients With Glioblastoma | completed | Phase 1 | 17 | Susan ChangOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT04801147 | Immunotherapy With Autologous Tumor Lysate-Loaded Dendritic Cells In Patients With Newly Diagnosed Glioblastoma Multiforme(DENDR1) | completed | Phase 1 / Phase 2 | 76 | Fondazione I.R.C.C.S. Istituto Neurologico Carlo BestaOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT04417088 | Exablate Blood-Brain Barrier Disruption for the Treatment of rGBM in Subjects Undergoing Carboplatin Monotherapy | completed | Phase 1 / Phase 2 | 28 | InSightecINDUSTRY | 1 | Mar 20, 2026 | clinicaltrials |
| NCT02115074 | Safety of Fluvastatin-Celebrex Association in Low-grade and High Grade Optico-chiasmatic Gliomas(FLUVABREX) | completed | Phase 1 | 20 | Centre Oscar LambretOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT01165333 | Cilengitide in Combination With Irradiation in Children With Diffuse Intrinsic Pontine Glioma(CILENT) | completed | Phase 1 | 32 | Centre Oscar LambretOTHER | 1 | Mar 16, 2026 | clinicaltrials |
| NCT04716699 | Systemic and Local Levels of Lidocaine During Surgery for the Removal of Glioblastoma | completed | Phase 1 | 12 | University of California, DavisOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT02669173 | Capecitabine + Bevacizumab in Patients With Recurrent Glioblastoma | completed | Phase 1 | 12 | Case Comprehensive Cancer CenterOTHER | 1 | Feb 23, 2026 | clinicaltrials |
| NCT03429803 | DAY101 In Gliomas and Other Tumors | completed | Phase 1 | 44 | Karen D. Wright, MDOTHER | 1 | Feb 19, 2026 | clinicaltrials |
| NCT05938387 | Safety and Tolerability of CVGBM in Adults With Newly Diagnosed MGMT-Unmethylated Glioblastoma or Astrocytoma | completed | Phase 1 | 37 | CureVacINDUSTRY | 3 | Feb 18, 2026 | clinicaltrials |
| NCT02073994 | Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation | completed | Phase 1 | 174 | Institut de Recherches Internationales ServierOTHER | 2 | Feb 17, 2026 | clinicaltrials |
| NCT02481154 | Study of Orally Administered AG-881 in Patients With Advanced Solid Tumors, Including Gliomas, With an IDH1 and/or IDH2 Mutation | completed | Phase 1 | 95 | Institut de Recherches Internationales ServierOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT03343197 | Study of AG-120 and AG-881 in Subjects With Low Grade Glioma | completed | Phase 1 | 49 | Institut de Recherches Internationales ServierOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT03529448 | TN-TC11G (THC+CBD) Combination With Temozolomide and Radiotherapy in Patients With Newly-diagnosed Glioblastoma(GEINOCANN) | completed | Phase 1 / Phase 2 | 33 | Grupo Español de Investigación en NeurooncologíaOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT03681028 | Feasibility of Individualized Therapy for Recurrent Glioblastoma | completed | Phase 1 | 30 | Jennifer ClarkeOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT03581942 | Copanlisib With Ibrutinib for Patients With Recurrent/ Refractory Primary Central Nervous System Lymphoma (PCNSL) | completed | Phase 1 / Phase 2 | 18 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 9, 2026 | clinicaltrials |
| NCT02315326 | Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Newly Diagnosed or Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL) | completed | Phase 1 / Phase 2 | 93 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 2, 2026 | clinicaltrials |
| NCT03703167 | Ibrutinib With Rituximab and Lenalidomide for Patients With Recurrent/Refractory Primary or Secondary Central Nervous System Lymphoma (PCNSL/SCNSL) | completed | Phase 1 | 25 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT04440358 | Exablate Blood-Brain Barrier Disruption With Carboplatin for the Treatment of rGBM | completed | Phase 1 / Phase 2 | 13 | InSightecINDUSTRY | 3 | Jan 20, 2026 | clinicaltrials |
| NCT04134117 | Tisagenlecleucel In Primary CNS Lymphoma | completed | Phase 1 | 13 | Matthew J. Frigault, M.D.OTHER | 1 | Jan 9, 2026 | clinicaltrials |
| NCT06095375 | Regorafenib With Temozolomide With or Without RT in MGMT-Methylated, IDH Wild-type GBM Patients(REGOMA-2) | completed | Phase 1 | 21 | Istituto Oncologico Veneto IRCCSOTHER | 1 | Jan 9, 2026 | clinicaltrials |
| NCT04295759 | INCB7839 in Treating Children With Recurrent/Progressive High-Grade Gliomas | completed | Phase 1 | 13 | Pediatric Brain Tumor ConsortiumNETWORK | 1 | Jan 5, 2026 | clinicaltrials |
| NCT02709226 | Dose Escalation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma | completed | Phase 1 | 17 | National Cancer Institute (NCI)NIH | 1 | Dec 31, 2025 | clinicaltrials |
| NCT04474353 | Study of Tumor Treating Fields With Hypofractionated Chemoradiotherapy in Newly Diagnosed Glioblastoma | completed | Phase 1 | 12 | Stanford UniversityOTHER | 1 | Dec 26, 2025 | clinicaltrials |
| NCT02473380 | Fluorescence Spectroscopy Guided Surgery(GLIOSPECT) | completed | Phase 1 | 11 | Hospices Civils de LyonOTHER | 1 | Dec 19, 2025 | clinicaltrials |
| NCT03638167 | EGFR806-specific CAR T Cell Locoregional Immunotherapy for EGFR-positive Recurrent or Refractory Pediatric CNS Tumors | completed | Phase 1 | 11 | Seattle Children's HospitalOTHER | 1 | Dec 17, 2025 | clinicaltrials |
| NCT04116658 | First-in-Human, Phase 1b/2a Trial of a Multipeptide Therapeutic Vaccine in Patients With Progressive Glioblastoma(ROSALIE) | completed | Phase 1 / Phase 2 | 100 | EnteromeINDUSTRY | 4 | Nov 28, 2025 | clinicaltrials |
| NCT03224104 | Multi-kinase Inhibitor TG02 (TG02) in Elderly Newly Diagnosed or Adult Relapsed Patients With Anaplastic Astrocytoma or Glioblastoma.(STEAM) | completed | Phase 1 | 71 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 5 | Nov 26, 2025 | clinicaltrials |
Data updated 5 days agoSource updated Sep 24, 2026source: clinicaltrials